CL2024001237A1 - Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos - Google Patents

Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos

Info

Publication number
CL2024001237A1
CL2024001237A1 CL2024001237A CL2024001237A CL2024001237A1 CL 2024001237 A1 CL2024001237 A1 CL 2024001237A1 CL 2024001237 A CL2024001237 A CL 2024001237A CL 2024001237 A CL2024001237 A CL 2024001237A CL 2024001237 A1 CL2024001237 A1 CL 2024001237A1
Authority
CL
Chile
Prior art keywords
antibodies
factor
clot formation
domain
methods
Prior art date
Application number
CL2024001237A
Other languages
English (en)
Spanish (es)
Inventor
Chalothorn Dan
Morton Lori
Lai Kehdih
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2024001237A1 publication Critical patent/CL2024001237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2024001237A 2021-10-22 2024-04-19 Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos CL2024001237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163270629P 2021-10-22 2021-10-22

Publications (1)

Publication Number Publication Date
CL2024001237A1 true CL2024001237A1 (es) 2024-09-13

Family

ID=84360943

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001237A CL2024001237A1 (es) 2021-10-22 2024-04-19 Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos

Country Status (12)

Country Link
US (1) US12304969B2 (https=)
EP (1) EP4419142A2 (https=)
JP (1) JP2024539157A (https=)
KR (1) KR20240099304A (https=)
CN (1) CN118414168A (https=)
AU (1) AU2022368930A1 (https=)
CA (1) CA3235457A1 (https=)
CL (1) CL2024001237A1 (https=)
CO (1) CO2024006258A2 (https=)
IL (1) IL312308A (https=)
MX (1) MX2024004849A (https=)
WO (1) WO2023070097A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
TWI736575B (zh) * 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
CA3125303A1 (en) 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof

Also Published As

Publication number Publication date
EP4419142A2 (en) 2024-08-28
CN118414168A (zh) 2024-07-30
KR20240099304A (ko) 2024-06-28
WO2023070097A2 (en) 2023-04-27
AU2022368930A1 (en) 2024-05-02
US12304969B2 (en) 2025-05-20
US20230131338A1 (en) 2023-04-27
IL312308A (en) 2024-06-01
MX2024004849A (es) 2024-05-06
CA3235457A1 (en) 2023-04-27
WO2023070097A3 (en) 2023-06-08
CO2024006258A2 (es) 2024-06-27
JP2024539157A (ja) 2024-10-28

Similar Documents

Publication Publication Date Title
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
Moro et al. Contractile activity of the bladder urothelium/lamina propria and its regulation by nitric oxide
Sanna et al. The HDAC1/c-JUN complex is essential in the promotion of nerve injury-induced neuropathic pain through JNK signaling
Yu et al. Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y6 activation of the phospholipase C/inositol trisphosphate pathway
EA201792304A1 (ru) Комбинированная терапия для лечения рака
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
CO6620068A2 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
Kim et al. The adenosine A3 receptor agonist Cl-IB-MECA induces cell death through Ca2+/ROS-dependent down regulation of ERK and Akt in A172 human glioma cells
CO2021001172A2 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
Xu et al. Inhibition of the mitochondrial unfolded protein response by acetylcholine alleviated hypoxia/reoxygenation-induced apoptosis of endothelial cells
Fu et al. 1, 6-di-O-caffeoyl-β-D-glucopyranoside, a natural compound from Callicarpa nudiflora Hook impairs P2Y12 and thromboxane A2 receptor-mediated amplification of platelet activation and aggregation
EA201891714A1 (ru) Галогензамещенные пиперидины в качестве модуляторов орексинового рецептора
CL2023002135A1 (es) Proteínas de unión al antígeno complemento c3
He et al. Blue LED causes autophagic cell death in human osteosarcoma by increasing ROS generation and dephosphorylating EGFR
Lee et al. Progesterone inhibits endothelial cell migration through suppression of the rho activity mediated by cSrc activation
Zrelli et al. Combined treatment of Hydroxytyrosol with carbon monoxide‐releasing Molecule‐2 prevents TNFα‐induced vascular endothelial cell dysfunction through NO production with subsequent NFκB inactivation
Jeon et al. Schizonepeta tenuifolia inhibits collagen stimulated platelet function via suppressing MAPK and Akt signaling
CL2024001237A1 (es) Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos
Protić et al. Effect of wine polyphenol resveratrol on the contractions elicited electrically or by norepinephrine in the rat portal vein
Raffetto et al. Ca2+− dependent contraction by the saponoside escin in rat vena cava: Implications in venotonic treatment of varicose veins
CO2025007349A2 (es) Anticuerpos de unión al dominio catalítico del factor xi y métodos de uso de estos
Romero-Imbachi et al. Centruroides margaritatus scorpion complete venom exerts cardiovascular effects through alpha-1 adrenergic receptors
Vadas The platelet-activating factor pathway in food allergy and anaphylaxis